Introduction
============

Intellectual disability (ID) is a common neurodevelopmental disorder with an onset of cognitive impairment before the age of 18 years^[@bib1],\ [@bib2],\ [@bib3]^ and is characterized by significant limitations in intellectual functioning and adaptive behavior.^[@bib1]^ The disease affects 1--3% of the world population; however, its prevalence in the developing world is almost twice that of the affluent world.^[@bib4],\ [@bib5]^ The causes of nearly 40% of ID remain ambiguous.^[@bib6]^ Among the known causes, \~50% of ID cases have an environmental etiology such as poor nutrition, multiple pregnancies with little gap, prenatal/perinatal brain ischemia, postnatal infections and inadequate medical services. The other half of ID cases has a genetic etiology, such as chromosomal abnormalities or mutations in specific genes.^[@bib3],\ [@bib5]^

In the western world, *de novo* heterozygous mutations and genomic copy number changes account for the majority of ID cases.^[@bib7]^ In contrast, recessive ID appears to be more common in consanguineous populations. Identification of gene mutations that cause non-syndromic autosomal recessive ID (ARID) has been notoriously slow because of the scarcity of sizeable families. By 2006, only three genes, *CC2D1A*, *CRBN* and *PRSS12* had been associated with ARID.^[@bib8],\ [@bib9],\ [@bib10]^ After 2006, research studies involving highly inbred populations from North Africa, the Middle East and South East Asia, greatly accelerated the pace of identification of gene mutations that cause ARID. These studies were further augmented by the use of next-generation sequencing. In 2011, Najmabadi *et al.*^[@bib11]^ applied targeted next-generation sequencing to 136 consanguineous Iranian families, in which homozygosity mapping had previously identified a locus, and reported 23 known and 50 new candidate ARID genes. More recently, exome sequencing (ES) of 143 large consanguineous Saudi Arabian families revealed 33 novel candidate genes involved in different neurological disorders.^[@bib12]^ These studies further highlighted the clinical and genetic complexity of ID and other neurodevelopmental disorders. Intriguingly, not a single gene with pathogenic variants emerged across various populations. Despite this progress, a large number of potential pathogenic gene mutations remain unidentified and warrant further studies in extended families from communities with endogamy.

Consanguineous marriages are practiced by about 20% of the human population, and the extent of consanguinity varies among different citizenry in the world. The rate of consanguineous marriages is 38% in Iran,^[@bib13],\ [@bib14]^ over 40% in several Middle Eastern countries^[@bib15]^ and above 50% in Pakistan.^[@bib16]^ The elevated level of endogamy in Pakistan has led to the increased prevalence of genetic disorders, including ARID, with an average of 1.1 cases of severe ID and 6.2 cases of mild ID per 100 live births.^[@bib17]^ The present study is designed to identify pathogenic gene mutations that cause ARID in the highly inbred population of Pakistan. In all, 121 families of 8 different ethnicities, exhibiting recessive ID, were enrolled mostly from the rural population of Pakistan. Through a systematic exome-sequencing approach we have identified potential pathogenic variants in 68 of these families: 30 families with a single homozygous DNA variant affecting previously known ID genes and another 30 families with a single homozygous or compound heterozygous variants in novel candidate ID genes. In eight families multiple homozygous variants were identified. We report the phenotype--genotype relationships, the predicted pathogenicity of the newly discovered candidate genes, their co-expression in functional networks in the developing and adult human brain, and possible involvement in various cellular processes.

Materials and methods
=====================

Family ascertainment and phenotype analysis
-------------------------------------------

This study was approved by the Institutional Review Board of the Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore, Pakistan and the Medical Ethical Committee Arnhem-Nijmegen, The Netherlands. The families of our cohort were obtained mainly from the rural populations of all five provinces of Pakistan ([Supplementary Tables S1 and S2](#sup1){ref-type="supplementary-material"}). Written informed consents were obtained from healthy adult subjects and the parents/legal guardians of minor subjects and ID patients. Specific informed consent was obtained for showing images of patients ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Participating individuals were evaluated with medical history interviews, and ID-related phenotypic features of patients were recorded. All affected individuals were clinically evaluated by both a geneticist and a general medical practitioner, with particular attention to neurological, morphological, ophthalmological, dermatological and skeletal symptoms. Photographs of the face and uncovered limbs were also taken ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). In some cases, magnetic resonance imaging and computerized tomography scans were also obtained. A description of developmental milestones was used to evaluate the severity of ID.^[@bib18]^ Only families with confirmed existence of cognitive dysfunction in the affected members were included in this study. Peripheral blood samples were collected from participating subjects. Genomic DNA was isolated following standard procedures.^[@bib19]^

Exome sequencing and variant selection
--------------------------------------

Exome enrichment and high-throughput sequencing were performed at the Radboudumc (Nijmegen, The Netherlands), The Wellcome Trust Sanger Institute (Hinxton, as part of the UK10K study) and the University of Maryland as previously described.^[@bib20]^ Selection of high-quality, potentially pathogenic variants was performed using seven major filtration steps ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"} and [Supplementary Methods](#sup1){ref-type="supplementary-material"}).

Sanger sequencing
-----------------

ES results were confirmed by Sanger sequencing. Primers for the amplification of the exons carrying variants were designed by using Primer3 (ref. [@bib21]; [Supplementary Tables S9 and S10](#sup1){ref-type="supplementary-material"}).

Predicted involvement of candidate genes in cellular processes and pathways
---------------------------------------------------------------------------

We researched the available literature and extracted all reported protein--protein interactions involving the known and the newly identified ID proteins and then entered them into a set of protein--protein interaction networks via the STRING^[@bib22]^ and MATISSE^[@bib23]^ algorithms, which are included in the EXPANDER package tools.^[@bib24]^

Expression of candidate genes in the human brain
------------------------------------------------

Brain expression analyses for new ARID genes were conducted using existing data sets in the BrainSpan: Atlas of the Developing Human Brain.^[@bib25]^ Normalized gene expression levels for 26 different brain tissues from 31 different developmental periods were obtained from the BrainSpan RNA-seq data set v3 (<http://brainspan.org>) of the developing human brain.

Co-expression network analysis
------------------------------

Networks of functionally co-expressed genes were identified by using the model of Gulsuner *et al.*^[@bib26]^ Using the BrainSpan database, gene pairs are defined as connected if the absolute value of the Pearson's correlation coefficient is \>0.8 for their expression levels in different brain regions (frontal cortex, temporal-parietal, sensory--motor and sub-cortical) and different developmental stages (fetal, infancy to late childhood and adolescence to adulthood), totaling 12 different networks. For each of these networks the numbers of edges (connections) between each of the novel ID genes was calculated. Random simulations of 10 000 replicates of an equal number of genes randomly selected from the BrainScan database were conducted to establish the significance of the connections. This provided a distribution of edges to estimate an empirical *P*-value for our novel ID genes.

In addition, we also randomly selected genes from the BrainScan database with an HGNC gene symbol, as well as at least one connection in the temporal region network. We compared an equal number of genes in this set with our ID genes that passed the same filtering criterion, which provided more conservative and consistent *P*-values.

Results
=======

Recruitment of families
-----------------------

We enrolled a cohort of 121 ID families with a likely autosomal recessive inheritance pattern mostly from the rural areas of Punjab, Sindh, Baluchistan, Khyber Pakhtoon Khawa and Northern areas. The enrolled families comprise eight ethnic groups, namely Punjabi (68.6%), Siraiki (10.8%), Pathan (9%), Urdu speaking (7.8%) and others (Sindhi, Afghan, Baloch and Kashmiri (3.8%); [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Every family had two or more affected individuals (except PKMR51a) and 111 families had consanguineous unions, while in 74 families the affected individuals were present in separate sibships ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}).

Genetic analysis
----------------

Before ES, the presence of disease-causing copy number variations was excluded by SNP microarray analysis (Affymetrix 250 K SNP array or higher coverage). ES was carried out for DNA samples of 1--3 individuals per family. Selection of the nucleotide variants was performed using the seven-tier filtering strategy ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). Sanger sequencing confirmed 359 candidate pathogenic variants. Of these, 80 variants in 77 genes segregated with the ID phenotype. There are six categories of evidence that we are using in this study to support an assertion that a variant is potentially pathogenic. These are (1) segregation analysis; (2) either absence in the dbSNP142 database or a very low allele frequency (\<0.01) in the ExAC Browser database; (3) absence in 213 ethnically matched control individuals; (4) a CADD score \>20; (5) pathogenicity prediction by multiple *in silico* programs; and (6) enrichment of loss-of-function (LOF) and potentially pathogenic variants of known and novel ID genes in patients with ID as compared with individuals with the non-ID phenotype (*n*=213; [Supplementary Table S3](#sup1){ref-type="supplementary-material"}).

Pathogenic variants identified in previously reported ARID genes
----------------------------------------------------------------

We identified 34 predicted pathogenic variants in 32 genes previously associated with ID or related neurodevelopmental disorders ([Tables 1](#tbl1){ref-type="table"} and 3a; [Supplementary Figures S3 and S6](#sup1){ref-type="supplementary-material"}). These variants include homozygous missense (*n*=21), nonsense (*n*=5), frameshift (*n*=5) and splice site variants (*n*=3). Twenty-five of these variants are novel ([Tables 1](#tbl1){ref-type="table"} and 3a). All new variants segregated with the disease and were either absent in dbSNP142 or had an allele frequency ⩽0.002 in the ExAC Browser^[@bib27]^ ([Tables 1](#tbl1){ref-type="table"} and 3a).

Most genes were found to be mutated in only one family, suggesting a low incidence of founder mutations underlying ID in the Pakistani population. Two genes, *TMEM67* and *FRAS1*, which carried different variants in two independent families ([Tables 1](#tbl1){ref-type="table"} and 3a). Two families (PKMR61b and PKMR69) carry one homozygous variant each in two unrelated but known ID genes. PKMR61b has variants in *TMEM67* and *FGFR1* while PKMR69 has variants in *FRAS1* and *EXOSC8* (Table 3a; [Supplementary Figure S6](#sup1){ref-type="supplementary-material"}). No carriers of these variants, which were both predicted to be damaging and disease causing, were detected in our population-specific controls. Two families each harbored a variant in an X-linked gene (*ZNF41* and *FLNA*).

A comparison of the phenotypes of 34 variants in genes known to cause ID shows that in most families the phenotype is similar to the reported entity ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}). Some deviations do occur, which may result from variable effects of allelic mutations or the effects of genetic modifier variants, which may be particularly relevant in populations with a high consanguinity rate.^[@bib28],\ [@bib29]^

Pathogenic variants identified in novel candidate ARID genes
------------------------------------------------------------

In 30 families we identified plausible pathogenic variants affecting a single gene that had not been previously implicated in ARID ([Table 2](#tbl2){ref-type="table"}; [Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). The majority of these changes were missense variants (*n*=23). In addition, we identified frameshift (*n*=6), nonsense (*n*=1) and splice site (*n*=1) variants that result in a truncated protein or are predicted to result in nonsense-mediated RNA decay. None of the variants were found in 213 unrelated, ethnically matched control individuals, indicating that they are not indigenous Pakistani polymorphisms. Clustal W (<http://www.ebi.ac.uk/Tools/msa/clustalw2/>) alignment of protein sequences encompassing the missense variants showed that most of the mutated amino acids are evolutionarily conserved ([Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). In 9 of the families there were no notable clinical characteristics besides ID, whereas 21 families exhibited syndromic forms of ID ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}).

In family PKMR159 a compound heterozygous change was detected in *AACS* and both variants have a frequency \<0.0002 in the ExAC database^[@bib27]^ ([Table 2](#tbl2){ref-type="table"}). *In silico* programs support a pathogenic nature of these variants, suggesting that both alleles are pathogenic and may contribute to the ID phenotype. In family PKMR72 a synonymous change (c.2232A\>G, p.(Arg813Arg)) was identified in *MDGA2* in the acceptor splice site of exon 13, which is predicted to affect splicing by three splice prediction programs (NNSPLICE^[@bib30]^, HSF^[@bib31]^ and MaxEntScan^[@bib32]^).

In eight families, variants in more than one gene were identified ([Tables 3a](#tbl3a){ref-type="table"} and [3b](#tbl3b){ref-type="table"},; [Supplementary Figure S6](#sup1){ref-type="supplementary-material"}). Four of these genes have already been implicated in a neurological disease (*TMEM67*, *FGFR1*, *FRAS1* and *EXOSC8*), but most variants affect genes that have not previously been connected to human disease phenotypes. Of the 19 co-segregating variants, 18 are missense variants and 1 is a splice site mutation. The identification of multiple variants co-segregating with the disorder suggests the possible existence of composite phenotypes ([Supplementary Table S6](#sup1){ref-type="supplementary-material"}), which might be a relatively common phenomenon in consanguineous populations.

Next, to determine the functional effect of variants, especially missense, on the secondary structure, stability and interactions of novel candidate ID proteins, we performed *in silico* molecular modeling using the HOPE and Pyre2 web-based programs. On the basis of the amino-acid sequence and structural homology with proteins with resolved crystal structures, we evaluated the effect of novel missense alleles in new ID proteins ([Supplementary Figure S7](#sup1){ref-type="supplementary-material"}). The identified variants are predicted to alter the function of the encoded proteins through their effect (loss off ionic interactions, loss of external interactions, de-stabilization of the core or the provision of more rigidity) on the secondary structure ([Supplementary Figure S7](#sup1){ref-type="supplementary-material"}).

Newly identified ARID proteins participate in essential regulatory networks
---------------------------------------------------------------------------

Next, we applied Ingenuity Pathway Analysis^[@bib33]^ to visualize the interactions between the 485 previously reported ID proteins (<http://gfuncpathdb.ucdenver.edu/iddrc/iddrc/GeneQuest.php>) and our novel candidate ID genes to identify the biological pathways underlying the disease process. The overall analysis, which includes physical interactions, co-expression, activation, inhibition and protein--RNA interactions, suggests that most novel ARID candidate proteins are part of already-established molecular ID gene networks ([Figure 1b](#fig1){ref-type="fig"}). By taking only physical interactions into account, we found the integration of several new ARID candidate proteins in oxidative phosphorylation, mitochondrial dysfunction, PTEN signaling and PPAR/RXR activation (*P\<*0.0001; [Figure 1a](#fig1){ref-type="fig"}).

Functional co-expression networks of ARID genes
-----------------------------------------------

To gain insight into the spatio-temporal expression pattern of the new candidate ARID genes, we extracted the mRNAseq data from the Allen Brain Atlas^[@bib34]^ and analyzed the expression patterns in developing and adult human brain tissues ([Supplementary Tables S7 and S8](#sup1){ref-type="supplementary-material"}). All new candidate ARID genes are expressed in the human brain from a very early development stage to adulthood ([Supplementary Table S8](#sup1){ref-type="supplementary-material"}).

When examining the co-expression functional networks for our genes from the BrainScan database, we find that they are significantly (Bonferroni-corrected *α*⩽0.0042) co-expressed in the adult brain in all four brain regions and that they are significantly (Bonferroni-corrected *P*-value \<0.0001) co-expressed in the temporal--parietal and sub-cortical regions from infancy to late childhood ([Figure 2a](#fig2){ref-type="fig"}). The phenotype observed in most of our ID families is established at birth, so to further evaluate co-expression during embryonic stages, we re-examined the normalized mRNAseq data at various post-conception weeks (p.c.w.). We found significant co-expression of ID genes in the frontal cortex region from 12 p.c.w. onwards ([Figure 2b](#fig2){ref-type="fig"}). Later in embryonic development (24--37 p.c.w.) ID genes are also co-expressed in the temporal--parietal and sub-cortical regions ([Figure 2b](#fig2){ref-type="fig"}), which persisted from infancy to late childhood ([Figure 2a](#fig2){ref-type="fig"}).

Discussion
==========

We report the results of ES in a cohort of 121 consanguineous Pakistani families. Likely causative variants in known ID genes were identified in 30 of these families. In addition, a single likely pathogenic variant affecting genes not previously implicated in ID was identified in 30 families, and 8 families had multiple variants segregating with the ID phenotype ([Figure 3](#fig3){ref-type="fig"}). Replication of this study in independent families is warranted to add these genes to the rapidly growing list of bona fide genes implicated in ID. In fact, during the submission phase of this manuscript-independent mutations in ARID phenotypes were already reported for two genes: *DPH1* (ref. [@bib35]) and *TANGO2*.^[@bib36],\ [@bib37]^ Other arguments that strengthen the involvement of the candidate ID genes are the disruptive nature of missense mutations as observed by modeling of the protein structure ([Supplementary Figure S7](#sup1){ref-type="supplementary-material"}), the co-occurrence of ARID candidate genes in common regulatory pathways ([Figure 1](#fig1){ref-type="fig"}) and the co-expression of these genes in distinct regions of the human brain ([Figure 2](#fig2){ref-type="fig"}). Further credit for the involvement of the new candidate ID genes is provided by the pattern of mutations. The frequency of predicted LOF alleles (that is, nonsense, frameshift or splice site variants) in known ID genes is 13/34 (38.24%), whereas their occurrence for new candidate genes is 8/30 (26.67%), and only 1/15 (6.67%) for candidate genes in families with multiple segregating variants. These LOF variants in the new candidate genes, *METTL4*, *METTL5*, *CAPN12*, *MDGA2*, *UBE2J2*, *CCDC82*, *PUS7*, *SLC7A10* and *TBC1D23*, have the highest confidence of causality. In addition, we analyzed the exomes of 213 unrelated Pakistani control individuals for variants affecting the known ID genes and the novel candidate ID genes that we have identified in our cohort. Importantly, homozygous and compound heterozygous variants that would have passed our stringent filtering criteria were identified in eight different genes. Five of these are known ID genes (*APTX*, *ASPM*, *FLNA*, *POMT2* and *SYNE1*), and only three are new candidate ID genes, of which two were found in families with multiple segregating variants (*ESYT3* and *SLC45A4*) and one affecting a gene (*GGN*) that harbored the single segregating variant in the respective family. The relative high occurrence of LOF alleles in families with single segregating variants, as well as the paucity of predicted pathogenic variants in these genes in a control cohort provides strong support for the involvement of the candidate ID genes listed in [Table 2](#tbl2){ref-type="table"}.

Recently, ES of 3222 apparently healthy British adults of Pakistani heritage revealed 1111 rare homozygous variants in 781 genes, including a frameshift allele (c.658_659delAA) in one of the novel candidate genes *CAPN12*.^[@bib38]^ No other homozygous LOF allele was observed in any novel ID candidate gene. We found the same frameshift allele ([Table 2](#tbl2){ref-type="table"}) segregating with a moderate ID phenotype ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}) in two affected individuals of family PKMR64 ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). There are at least three possible reasons to explain these observations. First, the LOF variant we identified in *CAPN12* is not causative for the moderate ID phenotype in family PKMR64, and *CAPN12* should be discarded as candidate ID gene. Second, without comprehensive assessment of mental health it is hard to rule out that the British--Pakistani individual has a mild ID phenotype similar to the phenotype in family PKMR64. Indeed, there are indications to question the health status of all individuals of the British--Pakistani cohort. For example, the reported genetic variants include homozygous LOF alleles in *AHI1*, *C12orf57* and *POMGNT1* genes, which are known to underlie the severe neurological disorders, Joubert syndrome^[@bib39]^, Temtamy syndrome^[@bib40]^ and muscle--eye--brain disease and other muscular dystrophy--dystroglycanopathies,^[@bib41]^ respectively. Variants identified in the British--Pakistani adults also include LOF alleles in *GJB2*, *MYO3A* and *COCH* genes, which are known to cause hearing loss in humans.^[@bib42],\ [@bib43],\ [@bib44]^ Third, there could be a protective or modifier genetic variant present in the British adult, which could render the effect of c.658_659delAA allele of *CAPN12.*^[@bib45],\ [@bib46]^

In the remaining 53 families, no high-confidence DNA variants was identified. This might be accounted for by several factors. First, it is possible that some causative variants have not passed our stringent filtering criteria. Second, genetic heterogeneity is likely to occur, even within some of the families we have studied. Such phenocopies would disrupt the segregation of DNA variants across all affected individuals in the studied pedigrees. Third, it is possible that some of the phenotypes with mild to moderate ID are caused by the digenic or oligogenic inheritance of rare variants or polymorphisms with low effect size. Finally, some mutations may have escaped detection by ES and may reside in non-coding regions or regions poorly covered by exonic enrichment.

Intellectual disability and other neurodevelopmental disorders
--------------------------------------------------------------

There is a growing body of evidence that categorical neurodevelopmental disorders such as ID, autism spectrum disorders, attention deficit/hyperactivity disorders and learning disorders lack precise boundaries in their clinical definitions, epidemiology, genetics, and molecular and cellular networks.^[@bib47],\ [@bib48],\ [@bib49],\ [@bib50],\ [@bib51],\ [@bib52]^ Accordingly, cognitive and behavioral comorbidities such as attention deficit/hyperactivity disorders, speech delay and aggression are also frequently seen in the ID families studied here. In our study, 21.88% of the families (7 of 32) with mutations in known genes ([Supplementary Tables S4 and S6](#sup1){ref-type="supplementary-material"}) and 33.33% of the families (12 of 36) with variants in novel candidate ARID genes resulting in clinical phenotypes that include epilepsy ([Supplementary Tables S5 and S6](#sup1){ref-type="supplementary-material"}). These results are not unexpected because the prevalence of epilepsy in individuals with some degree of ID ranges from 5.5 to 35%.^[@bib53]^ The prevalence of epilepsy grows with increasing severity of ID, with 15% of individuals with mild to moderate ID also exhibiting epilepsy and more than 30% of those with severe ID.^[@bib54]^ This high prevalence underscores the importance of identifying largely unknown common genetic factors with a causative role in epilepsy and ARID. A striking example is provided by family PKMR82, in which a homozygous nonsense mutation (p.Arg65\*) in *KCNA2* was associated with mild to moderate ID, speech delay, strabismus, walking delay and epilepsy. Recently, *de novo KCNA2* missense mutations were associated with epileptic encephalopathy, ataxia, variable ID^[@bib55],\ [@bib56]^ and other features reminiscent of those found in family PKMR82. These *de novo* missense mutations exert dominant effects by gain-of-function and dominant-negative mechanisms. The nonsense mutation in PKMR82 represents the first true LOF allele of *KCNA2*, which apparently has no phenotypic consequences in heterozygous mutation carriers.

Combinatorial ID phenotypes
---------------------------

We observed a syndromic ID phenotype in most of the studied families ([Supplementary Tables S4--S6](#sup1){ref-type="supplementary-material"}). These syndromic ID phenotypes could be attributed to the variant of a single gene in most families, but we have also observed multiple independently segregating variants in eight families (6.6%) of our cohort ([Tables 3a](#tbl3a){ref-type="table"} and [3b](#tbl3b){ref-type="table"}). This high co-occurrence of multiple potential disease-causing alleles may lead to the occurrence of composite recessive phenotypes. Both families PKMR61b and PKMR69 have segregating variants in two independent known disease genes. On the basis of the clinical presentation of previous mutations, in families PKMR61b and PKMR69 it seems that the core phenotypic features are attributable to just one of the two variants: *TMEM67* in family PKMR61b and *EXOSC8* in family PKMR69. Such inferences cannot be made for families in which segregating variants are seen in multiple novel candidate ID genes. For example, in family PKMR131 independent variants in *ESYT3* and *CCT6B* are associated with an unremarkable phenotype consisting of mild ID, speech delay, slow learning and aggressive behavior. *CCT6B* and *ESYT3* have not been connected to any human disorder so far, and therefore the variants in either or both of these genes could contribute to the phenotype.

Functional properties of novel ARID genes
-----------------------------------------

A comprehensive evaluation of the transcriptome profiles of normal human brain tissues revealed that the ID genes are significantly co-expressed in the frontal cortex region from 12 p.c.w. onwards, and in the temporal--parietal and sub-cortical regions from infancy to late childhood, implicating these regions in the pathogenesis of ID. These brain regions incorporate external and internal information and their disruptions have been associated with various disorders, such as amnesia, Alzheimer's disease and schizophrenia,^[@bib57]^ which further support the notion of shared molecular networks between various brain disorders. At later stages, we also found significant co-expression in the frontal cortex and sensory--motor regions ([Figure 2a](#fig2){ref-type="fig"}), which suggests that many of the ID genes might also have an important role in postnatal mechanisms, such as fine-tuning of synaptic connectivity, circuitry formation, and acute synaptic and other neural processes. Evidence for the involvement of postnatal mechanisms in ID is provided by studies with conditional (postnatal) knockout mice,^[@bib58],\ [@bib59]^ as well as studies with postnatal interventions in ID mouse models that are a basis of clinical trials for human ID disorders, such as Fragile X syndrome, Down syndrome and neurofibromatosis.^[@bib60],\ [@bib61],\ [@bib62]^

Common regulatory pathways involving new ARID genes
---------------------------------------------------

Only few of the novel ID genes seem to relate to molecular pathways and networks that have been previously implicated in dominant and X-linked forms of ID, such as pre- and post-synaptic signaling, transcription regulation and epigenetic mechanisms.^[@bib48],\ [@bib51],\ [@bib52]^ An exception is *UBE2J2*, encoding a ubiquitin-conjugating enzyme, which represents an emergent mechanism for regulating synapse function by post-translational modification through the ubiquitin pathway at the postsynaptic membrane.^[@bib63]^ Proteolysis by the ubiquitin proteosome pathway is recognized as a major molecular pathway leading to several neurodevelopmental^[@bib48]^ and neurodegenerative diseases.^[@bib64]^ Previously identified gene networks that are commonly disrupted in ID and other neurodevelopmental disorders are composed of genes that are highly dosage-sensitive. Thus, these pathways might represent other neurobiological processes than those that are affected by recessive mutations.

Conclusion
==========

Our study demonstrates the clinical utility of consanguineous populations for the elucidation of the molecular basis of very heterogeneous recessive disorders. Uncovering candidate genes for such disorders in inbred families will trigger the identification of matching mutations in other populations. In addition, a major strength of the present study is the presentation of the clinical profiles in conjunction with the reported candidate gene mutations. Therefore, the large collection of data presented in this manuscript is expected to facilitate the interpretation of DNA variants in diagnostic exome studies of patients with difficult-to-diagnose neurodevelopmental disorders. Future work using model systems may aid in unraveling and revealing the functional integration of different molecular networks in normal brain development and activity, which could add another level to neurological disorder diagnosis and more effective targeted therapy.
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![(**a**) Protein--protein interactions of novel candidates in different pathways. Novel candidate genes either directly interact with known intellectual disability (ID) genes (in blue) or through other genes (in gray) in the pathway. (**b**) Molecular functions of novel candidate genes (in red) for ID are indicated. Genes are involved in various cellular processes by activating, inhibiting and interacting with other molecules and are part of protein complexes.](mp2016109f1){#fig1}

![Co-expression of novel intellectual disability (ID) candidate genes was evaluated using RNA-seq data from the BrainSpan Atlas. (**a**) Gene pairs were defined as connected if the absolute value of the Pearson's correlation coefficient is \>0.8 for their expression levels in different brain region (frontal cortex, temporal--parietal, sensory--motor and sub-cortical) and different developmental stage (fetal, infancy to late childhood and adolescence to adulthood). Connections of co-expression genes at three development stages and four brain regions were plotted. Dotted lines indicate numbers of connections (edges) in networks created using target genes. Histograms represent distributions of the numbers of edges in 10 000 simulated networks using a similar number of random genes. \*Represents the significance enrichment with *P* less than adjusted *P*-value. **(b)** Co-expression of novel ID candidate genes during embryonic developmental stages for the same four brain regions.](mp2016109f2){#fig2}

![Overview of the results of genetic studies in 121 consanguineous Pakistani families segregating recessive intellectual disability (ID) phenotype.](mp2016109f3){#fig3}

###### Variants identified in known genes for intellectual disability or related disorders

  *Family*   *Gene*      *Position* [a](#t1-fn2){ref-type="fn"}   *Transcript*     *cDNA mutation* [b](#t1-fn3){ref-type="fn"}   *Protein change*          *Variation*          *CADD score v1.3*  *ExAC allele frequency x10* ^−*6*^   *OMIM*                               *Phenotype* [c](#t1-fn4){ref-type="fn"}
  ---------- ----------- ---------------------------------------- ---------------- --------------------------------------------- ------------------------- ------------------- ------------------- ------------------------------------ ----------------------------------- -----------------------------------------
  PKMR08     *GNE*       Chr9:36217445C\>T                        NM_005476.5      c.2086G\>A                                    p.(Val696Met)             Missense                   32.0         1942                                 603824                                                  D
  PKMR29     *POMT2*     Chr14:77765840T\>C                       NM_013382.5      c.881A\>G                                     p.(Tyr294Cys)             Missense                   27.9         0                                    607439                                                  O
  PKMR36     *APTX*      Chr9:32984803delC                        NM_001195248.1   c.638delG                                     p.(Arg213Leufs\*15)       Frameshift                  NA          8.238                                606350                                                  O
  PKMR42     *VPS13B*    Chr8:100654333C\>T                       NM_017890.4      c.5590C\>T                                    p.(Gln1864\*)             Nonsense                    NA          0                                    607817                                                  O
  PKMR51a    *TSHR*      Chr14:81610687C\>T                       NM_000369.2      **c.2285C\>T**                                **p.(Thr762Met)**         Missense                   25.3         8.247                                603372                                                  D
  PKMR61a    *SCN1A*     Chr2:166848284G\>A                       NM_001165963.1   c.5501C\>T                                    p.(Ala1834Val)            Missense                    32          8.241                                182389[d](#t1-fn5){ref-type="fn"}                       O
  PKMR79     *AP4M1*     Chr7:99704430delG                        NM_004722.3      **c.1287delG**                                **p.(Arg429Serfs\*15)**   Frameshift                  NA          0                                    602296                                                  O
  PKMR82     *KCNA2*     Chr1:111147212G\>A                       NM_004974.3      **c.193C\>T**                                 **p.(Arg65\*)**           Nonsense                    NA          8.239                                176262[d](#t1-fn5){ref-type="fn"}               C, inheritance D
  PKMR85     *MED23*     Chr6:131941859T\>C                       NM_004830.3      **c.506A\>G**                                 **p.(Tyr169Cys)**         Missense                   24.6         0                                    605042                                                  C
  PKMR86     *FRAS1*     Chr4:79202579C\>T                        NM_025074.6      **c.1099C\>T**                                **p.(Arg367Cys)**         Missense                   24.4         43.14                                607830                                                  O
  PKMR87     *MAN2B1*    Chr19:12763176C\>G                       NM_000528.3      **c.1928+1C\>G**                              **p.(Phe642Phefs\*2)**    Aberrant splicing           NA          0                                    609458                                                  O
  PKMR97     *MFSD2A*    Chr1:40431565C\>T                        NM_001136493.2   **c.632C\>T**                                 **p.(Thr211Met)**         Missense                    33          8.239                                614397                                                  C
  PKMR99     *SYNE1*     Chr6:152819877C\>G                       NM_182961.3      **c.939G\>C**                                 **p.(Lys313Asn)**         Missense                   21.9         28.33                                608441                                                  D
  PKMR102    *ASPM*      Chr1:197087007C\>T                       NM_018136.4      **c.3977G\>A**                                **p.(Trp1326\*)**         Nonsense                    NA          8.255                                605481                                                  C
  PKMR105    *ZNF41*     ChrX:47315776C\>T                        NM_007130.2      **c.94G\>A**                                  **p.(Val32Met)**          Missense                    30          0                                    314995                                                  O
  PKMR115    *SRD5A3*    Chr4:56212560G\>A                        NM_024592.4      c.57G\>A                                      p.Trp19\*                 Nonsense                    NA          357.1                                611715                                                  C
  PKMR119    *PGAP1*     Chr2:197710616T\>C                       NM_024989.3      **c.2276A\>G**                                **p.(Tyr759Cys)**         Missense                   23.6         16.57                                611655                                                  C
  PKMR133    *DOCK8*     Chr9:286599G\>A                          NM_203447.3      **c.295G\>A**                                 **p.(Glu99Lys)**          Missense                   25.9         247.3                                611432                                                  C
  PKMR151    *TMEM67*    Chr8:94768056G\>A                        NM_153704.5      c.274G\>A                                     p.(Gly92Arg)              Missense                   25.6         17.41                                609884                                                  O
  PKMR152    *WDR62*     Chr19:36587982G\>T                       NM_001083961.1   **c.2520+1G\>T**                              **p.(Leu840Leufs\*95)**   Aberrant splicing           NA          0                                    613583                                                  C
  PKMR184    *SPG11*     Chr15:44876109delA                       NM_025137.3      c.5769delT                                    p.(Ser1923Argfs\*28)      Frameshift                  NA          41.18                                610844                                                  C
  PKMR188    *ASPA*      Chr17:3402260G\>A                        NM_000049.2      c.820G\>A                                     p.(Gly274Arg)             Missense                   28.9         8.421                                608034                                                  C
  PKMR193    *ARL13B*    Chr3:93755508G\>A                        NM_182896.2      **c.599G\>A**                                 **p.(Arg200His)**         Missense                    34          8.314                                608922                                                  C
  PKMR212    *ZFYVE26*   Chr14:68268804_05delGA                   NM_015346.3      **c.1630_1631delTC**                          **p.(Ser544Leufs\*24)**   Frameshift                  NA          8.236                                612012                                                  C
  PKMR216    *AP4S1*     Chr14:31539047A\>G                       NM_007077.4      **c.139-2A\>G**                               **p.(Gln46Glnfs\*85)**    Aberrant splicing           NA          24.71                                607243                                                  C
  PKMR224    *MKKS*      Chr20:10393388delT                       NM_018848.3      **c.775delA**                                 **p.(Thr259Leufs\*21)**   Frameshift                  NA          74.18                                604896                                                  C
  PKMR242    *WDR73*     Chr15:85186864A\>G                       NM_032856.3      **c.974T\>C**                                 **p.(Phe325Ser)**         Missense                   29.9         0                                    616144                                                  O
  PKMR264    *FRY*       Chr13:32747633G\>A                       NM_023037.2      **c.2281G\>A**                                **p.(Val761Ile)**         Missense                   21.7         8.281                                614818                                                  O
  PKMR281    *GPT2*      Chr16:46956326C\>T                       NM_133443.3      **c.1210C\>T**                                **p.(Arg404\*)**          Nonsense                    NA          33.31                                138210                                                  O
  PKMR321    *FLNA*      ChrX:153583356G\>A                       NM_001110556.1   **c.5054C\>T**                                **p.Thr1685Met**          Missense                   27.1         11.58                                300017                                                  C

Abbreviations: C, concordant; D, discordant; NA, not applicable; O, overlapping features.

Chromosomal position according to GRCh37/hg19.

Novel mutations are written in bold font.

Concordance of the observed phenotype with the phenotype reported in Online Mendelian Inheritance in Man (OMIM).

Reported phenotypes show a dominant inheritance pattern, whereas the mutations reported here are homozygous.

###### Novel candidate genes for intellectual disability

  *Family*   *Ethnicity*      *Genes*                                *Position* [a](#t2-fn2){ref-type="fn"}   *Transcript*     *cDNA mutation*   *Protein change*      *Variation*         *Protein function*                          *CADD score v1.3*  *ExAC allele frequency x10* ^−*6*^
  ---------- ---------------- -------------------------------------- ---------------------------------------- ---------------- ----------------- --------------------- ------------------- ------------------------------------------ ------------------- ------------------------------------
  PKMR24     Punjabi          *ZSCAN25 (ZNF498)*                     Chr7:99219114A\>G                        NM_145115.2      c.506A\>G         p.(Glu169Gly)         Missense            Zinc finger protein nucleic acid binding          26.5         0
  PKMR33     Punjabi          *DPH1*                                 Chr17:1944817C\>T                        NM_001383.3      c.1144C\>T        p.(Pro382Ser)         Missense            Diphthamide biosynthesis                           32          8.515
  PKMR40     Pathan           *DCTN2*                                Chr12:57929561T\>G                       NM_001261412.1   c.173A\>C         p.(Lys58Thr)          Missense            Structural protein                                26.8         8.484
  PKMR43     Pathan           *METTL5*                               Chr2:170677663_64delTC                   NM_014168.3      c.344_345delGA    p.(Arg115Asnfs\*19)   Frameshift          Methyl transferase                                 NA          0
  PKMR45     Pathan           *TANGO2 (C22orf25)*                    Chr22:20041047G\>T                       NM_152906.5      c.353G\>T         p.(Gly118Val)         Missense            Transport and Golgi organization                  29.4         0
  PKMR64     Punjabi          *CAPN12* [b](#t2-fn3){ref-type="fn"}   Chr19:39230761_62delTT                   NM_144691.4      c.658_659delAA    p.(Asn220Glnfs\*25)   Frameshift          Cystine protease                                   NA          795.1
  PKMR66     Punjabi          *TBC1D8*                               Chr2:101652537G\>A                       NM_001102426.1   c.1501C\>T        p.(Leu501Phe)         Missense            G-protein modulator                               31.0         99.37
  PKMR67     Punjabi          *MSS51* *(ZMYND17)*                    Chr10:75187870G\>A                       NM_001024593.1   c.173C\>T         p.(Ser58Leu)          Missense            Zinc finger transcription factor                  33.0         140.1
  PKMR72     Punjabi          *MDGA2*                                Chr14:47343402T\>C                       NM_001113498.2   c.2232A\>G        p.(Arg744Arg)         Aberrant Splicing   GPI anchor                                         NA          52.83
  PKMR98     Punjabi          *FMOD*                                 Chr1:203316893C\>T                       NM_002023.4      c.506G\>A         p.(Arg169Gln)         Missense            Receptor                                          23.3         296.6
  PKMR118    Punjabi          *C22orf31*                             Chr22:29454885C\>G                       NM_015370.1      c.718G\>C         p.(Gly240Arg)         Missense            Unknown                                           28.6         0
  PKMR142    Punjabi          *SMARCA1*                              ChrX:128657269C\>T                       NM_139035.2      c.79G\>A          p.(Glu27Lys)          Missense            Component of NURF complex                         22.1         35.55
  PKMR153    Punjabi          *GPAA1*                                Chr8:145138854G\>C                       NM_003801.3      c.527G\>C         p.(Trp176Ser)         Missense            Glycosylphosphatidylinositol                      27.6         16.58
  PKMR155    Kashmiri         *OR2A12*                               Chr7:143792562G\>A                       NM_001004135.1   c.362G\>A         p.(Arg121Gln)         Missense            Olfactory receptor                                24.1         16.57
  PKMR159    Punjabi          *AACS*                                 Chr12:125612785A\>G                      NM_023928.3      c.1388A\>G;       p.(Asn463Ser);        Missense            Acetoacetyl-Co synthetase                         21.2         82.95
                                                                     Chr12:125621351C\>T                                       c.1822C\>T        p.(Arg608Cys)         Missense                                                              34.0         198.1
  PKMR164    Punjabi          *GGN*                                  Chr19:38877823G\>A                       NM_152657.3      c.79C\>T          p.(Arg27Cys)          Missense            Germ cell specific gene                           25.9         362.3
  PKMR174    Siraki           *MEGF9*                                Chr9:123421769C\>T                       NM_001080497.2   c.686G\>A         p.(Gly229Asp)         Missense            Receptor                                          26.8         59.54
  PKMR195    Siraki           *WFDC1*                                Chr16:84360517G\>A                       NM_021197.3      c.634G\>A         p.(Gly212Arg)         Missense            Protease inhibitor                                24.2         65.89
  PKMR198    Punjabi          *METTL4*                               Chr18:2554909G\>T                        NM_022840.4      c.588C\>A         p.(Cys196\*)          Nonsense            Methyl transferase                                 NA          41.19
  PKMR200    Siraiki          *UBE2J2*                               Chr1:1203295_96delTT                     NM_194315.1      c.77_78delAA      p.(Lys26Argfs\*30)    Frameshift          Ubiquitin protein ligase                           NA          0
  PKMR206    Siraiki          *CCDC82*                               Chr11:96117539delC                       NM_024725.3      c.373delG         p.(Asp125Ilefs\*6)    Frameshift          Unknown                                            NA          0
  PKMR213    Siraiki Baloch   *TMEM222*                              Chr1:27657230G\>A                        NM_032125.2      c.214G\>A         p.(Gly72Ser)          Missense            Transmembrane protein                             34.0         8.237
  PKMR215    Siraiki          *PUS7*                                 chr7:105148870_71delTG                   NM_019042.3      c.89_90delCA      p.(Thr30Lysfs\*20)    Frameshift          Pseudouridylate synthetase                         NA          8.237
  PKMR258    Punjabi          *AREL1*                                Chr14:75150203G\>A                       NM_001039479.1   c.277C\>T         p.(His93Tyr)          Missense            Ubiquitin-protein ligase                          23.1         1102
  PKMR298    Punjabi          *SEPT6*                                ChrX:118797529T\>C                       NM_145799.3      c.257A\>G         p.(Tyr86Cys)          Missense            Filament formation                                26.4         11.41
  PKMR318    Punjabi          *DUOX1*                                Chr15:45444197G\>T                       NM_175940.2      c.3140G\>T        p.(Cys1047Phe)        Missense            Oxidase                                           22.9         16.59
  PKMR320    Punjabi          *SLC7A10*                              Chr19:33700282_83dupA                    NM_019849.2      c.1372_1373dupA   p.(Thr458Asnfs\*71)   Frameshift          Transporter                                        NA          16.49
  PKMR325    Punjabi          *TM2D3*                                Chr15:102182749G\>A                      NM_078474.2      c.677C\>T         p.(Thr226Met)         Missense            Cell death or proliferation                       31.0         8.344
  PKMR326    Pathan           *PRKAR2B*                              Chr7:106797706G\>T                       NM_002736.2      c.1060G\>T        p.(Ala354Ser)         Missense            Kinase modulator                                  32.0         8.247
  PKMR396    Punjabi          *RGR*                                  Chr10:86008779G\>A                       NM_002921.3      c.350G\>A         p.(Arg117His)         Missense            Retinal G-protein coupled receptor                26.5         107.3

Abbreviations: GPI, Glycophosphatidylinositol; NA, Not Applicable.

Chromosomal position according to GRCh37/hg19.

This frameshift allele of *CAPN12* has been documented in apparently healthy British--Pakistani individual in a homozygous fashion.^[@bib35]^

###### Multiple known genes segregating in same families

  *Family*   *Ethnicity*   *Genes*    *Position* [a](#t3a-fn2){ref-type="fn"}   *Transcript*   *cDNA mutation*   *Protein change*   *Variation*   *Protein function*                           *CADD score V1.3*   *ExAC allele frequency x10* ^−*6*^   *OMIM*
  ---------- ------------- ---------- ----------------------------------------- -------------- ----------------- ------------------ ------------- -------------------------------------------- ------------------- ------------------------------------ --------
  PKMR61b    Punjabi       *TMEM67*   Chr8:94827616G\>A                         NM_153704.5    c.2848G\>A        p.(Val950Met)      Missense      Centriole migration to the apical membrane   32.0                8.516                                609884
                           *FGFR1*    Chr8:38271255G\>A                         NM_023110.2    c.2360C\>T        p.(Thr787Met)      Missense      Fibroblast growth factor receptor            29.2                126.8                                136350
  PKMR69     Punjabi       *FRAS1*    Chr4:79443907G\>A                         NM_025074.6    c.10753G\>A       p.(Ala3585Thr)     Missense      Extracellular matrix protein                 24.4                27.21                                607830
                           *EXOSC8*   Chr13:37580059C\>T                        NM_181503.2    c.241C\>T         p.(Pro81Ser)       Missense      Exosome component                            28.2                173.6                                606019

Abbreviations: OMIM, Online Mendelian Inheritance In Man.

Chromosomal position according to GRCh37/hg19.

###### Multiple novel candidate genes segregating in the same family

  *Family*   *Ethnicity*   *Genes*     *Position* [a](#t3b-fn2){ref-type="fn"}   *Transcript*     *cDNA mutation*   *Protein change*      *Variation*         *Protein function*                      *CADD score V1.3*   *ExAC allele frequency x10* ^−*6*^   *OMIM*
  ---------- ------------- ----------- ----------------------------------------- ---------------- ----------------- --------------------- ------------------- --------------------------------------- ------------------- ------------------------------------ --------
  PKMR30     Punjabi       *DGCR8*     Chr22:20073866G\>A                        NM_022720.6      c.380G\>A         p.(Ser127Asn)         Missense            miRNA biogenesis                        22.9                8.248                                609030
                           *FNIP2*     Chr4:159812659G\>T                        NM_020840.1      c.3011G\>T        p.(Trp1004Leu)        Missense            Folliculin-interacting protein          23.6                967.4                                612768
                           *GSTCD*     Chr4:106640368A\>G                        NM_001031720.3   c.578A\>G         p.(Asp193Gly)         Missense            Glutathione *S*-transferase             29.8                49.49                                615912
                           *TOP3B*     Chr22:22318366G\>T                        NM_003935.4      c.1133C\>A        p.(Pro378Gln)         Missense            Topoisomerase                           27.6                0                                    603582
  PKMR51b    Pathan        *CPT1B*     Chr22:51008816C\>T                        NM_152245.2      c.2048G\>A        p.(Arg683His)         Missense            Acetyltransferase                       35.0                164.2                                601987
                           *PHACTR1*   Chr6:13228209C\>T                         NM_030948.2      c.1148C\>T        p.(Ser383Leu)         Missense            Phosphatase and actin regulator         23.2                0                                    608723
  PKMR52     Pathan        *STX19*     Chr3:93733695A\>G                         NM_001001850.2   c.419T\>C         p.(Met140Thr)         Missense            SNARE protein                           24.1                82.42                                ---
                           *TBC1D23*   Chr3:100035033T\>G                        NM_001199198.2   c.1687+2T\>G      p.(Asp563Glyfs\*33)   Aberrant splicing   Rab GTPase activator                    NA                  0                                    ---
  PKMR65     Punjabi       *DNAJC2*    Chr7:102956464A\>G                        NM_014377.1      c.1499T\>C        p.(Ile500Thr)         Missense            Phosphoprotein                          29.7                75.31                                605502
                           *LINGO1*    Chr15:77907386T\>C                        NM_032808.6      c.863A\>G         p.(Tyr288Cys)         Missense            Cell signaling                          24.6                8.285                                609791
                           *VAPA*      Chr18:9945020A\>G                         NM_003574.5      c.517A\>G         p.(Arg173Gly)         Missense            Membrane protein                        21.6                0                                    605703
  PKMR120    Punjabi       *LRRC6*     Chr8:133669098A\>C                        NM_012472.4      c.234T\>G         p.(Ile78Met)          Missense            Receptor extracellular matrix protein   24.7                185.7                                614930
                           *SLC45A4*   Chr8:142228631C\>T                        NM_001080431.2   c.955G\>A         p.(Asp319Asn)         Missense            Solute carrier                          24.8                375.2                                ---
  PKMR131    Punjabi       *ESYT3*     Chr3:138191644C\>T                        NM_031913.3      c.2180C\>T        p.(Ser727Leu)         Missense            Extended synaptotagmin                  34                  124.3                                616692
                           *CCT6B*     Chr17:33285649C\>A                        NM_001193529.2   c.266G\>T         p.(Gly89Val)          Missense            Chaperonin-containing T-complex         31                  0                                    610730

Abbreviations: NA, Not Applicable; OMIM, Online Mendelian Inheritance In Man.

Chromosomal position according to GRCh37/hg19.
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